Opus Genetics (IRD) officer logs 3,950-share RSU tax withholding on Form 4

Rhea-AI Filing Summary

Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Fin. Quality Assurance, reported a share withholding related to equity compensation. On 01/10/2026, the issuer withheld 3,950 shares of common stock at $1.93 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. This was not an open market sale of securities, but an administrative tax withholding. After this transaction, Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zaremba Rabourn Amy

Role Head of Fin. Quality Assurance

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	3,950	$1.93	$8K

Holdings After Transaction: Common Stock — 110,018 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaremba Rabourn Amy

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Fin. Quality Assurance

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		F(1)		3,950	D	$1.93	110,018	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities.

	/s/ Amy Rabourn	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Opus Genetics (IRD) report for January 10, 2026?

On 01/10/2026, Opus Genetics officer Amy Zaremba Rabourn reported that the issuer withheld 3,950 shares of common stock at $1.93 per share to cover taxes from a restricted stock unit vesting.

Was the Amy Zaremba Rabourn Form 4 transaction an open market sale of Opus Genetics stock?

No. The footnote explains that the 3,950 shares were withheld by the issuer to satisfy tax withholding obligations from an RSU vesting and settlement event and was not an open market sale of securities.

How many Opus Genetics (IRD) shares does Amy Zaremba Rabourn own after the reported transaction?

Following the reported tax withholding on 01/10/2026, Amy Zaremba Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.

What is Amy Zaremba Rabourn’s role at Opus Genetics related to this Form 4?

Amy Zaremba Rabourn is reported as an officer of Opus Genetics, serving as Head of Fin. Quality Assurance, and the Form 4 reflects changes in her beneficial ownership of company stock.

What does transaction code "F" mean in the Opus Genetics (IRD) Form 4 filing?

Transaction code "F" indicates a payment of tax liability by delivering or withholding securities. In this case, Opus Genetics withheld 3,950 shares to cover taxes from an RSU vesting.

Is the reported Opus Genetics Form 4 filing a direct or indirect ownership change?

The filing shows the transaction in Common Stock as direct ownership (D), with 110,018 shares directly owned after the withholding event.